title: Synthesis of some novel 4-arylidene pyrazoles as potential antimicrobial agents.
abstract: BACKGROUND
  Pyrazole and pyrazolone motifs are well known for their wide range of biological activities such as antimicrobial, anti-inflammatory, and antitumor activities. The incorporation of more than one pharmacophore in a single scaffold is a well known approach for the development of more potent drugs. In the present investigation, a series of differently substituted 4-arylidene pyrazole derivatives bearing pyrazole and pyrazolone pharmacophores in a single scaffold was synthesized.
  
  
  RESULTS
  The synthesis of novel 4-arylidene pyrazole compounds is achieved through Knovenagel condensation between 1,3-diaryl-4-formylpyrazoles and 3-methyl-1-phenyl-1H-pyrazol-5-(4H)-ones in good yields. All compounds were evaluated for their in vitro antimicrobial activity.
  
  
  CONCLUSIONS
  A series of 4-arylidene pyrazole derivatives was evaluated for their in vitro antimicrobial activity against two Gram-positive (Bacillus subtilis and Staphylococcus aureus) and two Gram-negative bacteria (Pseudomonas fluorescens and Escherichia coli), as well as two pathogenic fungal strains (Candida albicans and Saccharomyces cerevisiae). The majority of the compounds displayed excellent antimicrobial profile against the Gram-positive (B. subtilis and S. aureus), and some of them are even more potent than the reference drug ciprofloxacin.
authors: Department of Chemistry, Kurukshetra University, Kurukshetra 136119, India. pksharma@kuk.ac.in.
authors: Poonam
authors: P
authors: Khloya
authors: Pawan
authors: P
authors: Kumar
authors: Arpana
authors: A
authors: Mittal
authors: Neeraj K
authors: NK
authors: Aggarwal
authors: Pawan K
authors: PK
authors: Sharma
references: Eur J Med Chem. 2011 Apr;46(4):1425-32
references: 21342734
references: Eur J Med Chem. 2010 Sep;45(9):3692-701
references: 20605657
references: Bioorg Med Chem Lett. 2004 Dec 20;14(24):6035-40
references: 15546724
references: Bioorg Med Chem. 2012 Jul 15;20(14):4237-44
references: 22739085
references: Eur J Med Chem. 2009 Sep;44(9):3480-7
references: 19268406
references: Eur J Med Chem. 2009 Sep;44(9):3784-7
references: 19464087
references: J Med Chem. 2010 Dec 23;53(24):8727-33
references: 21121633
references: Eur J Med Chem. 2007 Jul;42(7):934-9
references: 17321008
references: Org Med Chem Lett. 2011 Aug 03;1(1):5
references: 22373350
references: Eur J Med Chem. 2002 Aug;37(8):671-9
references: 12161064
references: Org Med Chem Lett. 2011 Nov 08;1(1):15
references: 22373217
references: Bioorg Med Chem. 2012 May 15;20(10):3306-16
references: 22516672
references: Eur J Med Chem. 2013 Jan;59:203-8
references: 23220649
references: Bioorg Med Chem. 2012 Jul 15;20(14):4430-6
references: 22705022
references: Chin J Cancer. 2010 Dec;29(12):980-7
references: 21114917
references: Bioorg Med Chem. 2010 Jul 1;18(13):4606-14
references: 20627597
references: Eur J Med Chem. 2005 Oct;40(10):977-90
references: 15961192
references: Eur J Med Chem. 2010 Jun;45(6):2650-5
references: 20171763
references: J Antimicrob Chemother. 2001 Jul;48 Suppl 1:5-16
references: 11420333
references: J Med Chem. 2012 Jan 12;55(1):515-27
references: 22191331